Lawrence Galitz

858 total citations
12 papers, 480 citations indexed

About

Lawrence Galitz is a scholar working on Pulmonary and Respiratory Medicine, Pharmacology and Genetics. According to data from OpenAlex, Lawrence Galitz has authored 12 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 2 papers in Pharmacology and 2 papers in Genetics. Recurrent topics in Lawrence Galitz's work include Chronic Lymphocytic Leukemia Research (2 papers), Chronic Myeloid Leukemia Treatments (2 papers) and Hepatitis C virus research (2 papers). Lawrence Galitz is often cited by papers focused on Chronic Lymphocytic Leukemia Research (2 papers), Chronic Myeloid Leukemia Treatments (2 papers) and Hepatitis C virus research (2 papers). Lawrence Galitz collaborates with scholars based in United States, Switzerland and United Kingdom. Lawrence Galitz's co-authors include Horst Schran, Chiaki Tanaka, Venkat Sethuraman, Ophelia Yin, Peter Hu, William H. Lyness, Gregory B. Holmes, Theodore A Smith, Oliver G. Ottmann and Francis J. Giles and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Lawrence Galitz

12 papers receiving 458 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lawrence Galitz United States 8 149 119 114 87 86 12 480
James Geib United States 10 71 0.5× 112 0.9× 57 0.5× 70 0.8× 57 0.7× 21 401
Glenda M. Davison South Africa 15 79 0.5× 167 1.4× 68 0.6× 43 0.5× 52 0.6× 44 607
M. Guéguen France 15 152 1.0× 80 0.7× 31 0.3× 83 1.0× 31 0.4× 34 575
Vincent Raimondi France 7 139 0.9× 75 0.6× 41 0.4× 90 1.0× 31 0.4× 7 453
José M. Hernández Spain 13 421 2.8× 77 0.6× 91 0.8× 63 0.7× 21 0.2× 26 715
Thao Doan United States 13 99 0.7× 24 0.2× 65 0.6× 126 1.4× 16 0.2× 35 543
Harvey G. Klein United States 8 66 0.4× 122 1.0× 87 0.8× 29 0.3× 33 0.4× 11 366
Carmen Mak United States 7 752 5.0× 65 0.5× 198 1.7× 219 2.5× 82 1.0× 11 1.2k
Ulrich Junge Germany 12 210 1.4× 169 1.4× 83 0.7× 65 0.7× 97 1.1× 32 617
Abbe Rubin United States 10 62 0.4× 65 0.5× 70 0.6× 38 0.4× 20 0.2× 13 563

Countries citing papers authored by Lawrence Galitz

Since Specialization
Citations

This map shows the geographic impact of Lawrence Galitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Galitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Galitz more than expected).

Fields of papers citing papers by Lawrence Galitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Galitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Galitz. The network helps show where Lawrence Galitz may publish in the future.

Co-authorship network of co-authors of Lawrence Galitz

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Galitz. A scholar is included among the top collaborators of Lawrence Galitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Galitz. Lawrence Galitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
3.
Wald, Anna, Lawrence Corey, Amalia Magaret, et al.. (2014). Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection. New England Journal of Medicine. 370(3). 201–210. 113 indexed citations
4.
Nicolas, Laurent B., Marcelo M. Gutierrez, Lawrence Galitz, & Jasper Dingemanse. (2011). Epoprostenol With Expanded Stability Has The Same Pharmacokinetic And Pharmacodynamic Profiles As Epoprostenol In Healthy Subjects. A5902–A5902. 1 indexed citations
5.
Tanaka, Chiaki, et al.. (2010). Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants. The Journal of Clinical Pharmacology. 51(1). 75–83. 57 indexed citations
6.
Tanaka, Chiaki, Ophelia Yin, Venkat Sethuraman, et al.. (2009). Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib. Clinical Pharmacology & Therapeutics. 87(2). 197–203. 126 indexed citations
7.
Marier, Jean‐Francois, James Lee, Lawrence Galitz, et al.. (2006). Effect of Repeated Oral Administrations of the Oral Adsorbent AST-120 on Serum Creatinine and Other Markers of Renal Function. American Journal of Nephrology. 26(2). 136–141. 18 indexed citations
8.
Palaparthy, Rameshraja, Rajendra Pradhan, Matthew J. Rieser, et al.. (2006). Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. Biopharmaceutics & Drug Disposition. 28(2). 65–71. 4 indexed citations
9.
Davé, Nisha, et al.. (2005). Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. British Journal of Clinical Pharmacology. 59(5). 598–601. 32 indexed citations
10.
Holmes, Gregory B., Lawrence Galitz, Peter Hu, & William H. Lyness. (2005). Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. British Journal of Clinical Pharmacology. 60(5). 469–476. 61 indexed citations
11.
Morrow, David A., Rafael F. Sequeira, Tim Henry, et al.. (2004). 861-3 A phase I open-label dose escalation trial of a monoclonal antibody against tissue factor (sunol cH36) in stable coronary artery disease: Results of the PROXIMATE-TIMI 27 trial. Journal of the American College of Cardiology. 43(5). A303–A303. 1 indexed citations
12.
MacGregor, Thomas R., et al.. (2004). Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers. HIV Clinical Trials. 5(6). 371–382. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James Geib Breakdown of academic impact, for papers by Glenda M. Davison Breakdown of academic impact, for papers by M. Guéguen Breakdown of academic impact, for papers by Vincent Raimondi Breakdown of academic impact, for papers by José M. Hernández Breakdown of academic impact, for papers by Thao Doan Breakdown of academic impact, for papers by Harvey G. Klein Breakdown of academic impact, for papers by Carmen Mak Breakdown of academic impact, for papers by Ulrich Junge Breakdown of academic impact, for papers by Abbe Rubin
Rankless by CCL
2026